Intra-subtype heterogeneity shapes treatment response in <i>KMT2A</i> -rearranged ALL across all age groupsAlina Hartmann, Claudia D. Baldus, Thomas Beder et al.|bioRxiv (Cold Spring Harbor Laboratory)|2025Cited by 1
Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in <i>KMT2A</i>-Rearranged BCP-ALLAlina Hartmann, Claudia D. Baldus, Lorenz Bastian et al.|Blood|2024Cited by 0
IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy responseSonja Bendig, Lorenz Bastian, Alina Hartmann et al.|Blood|2026Cited by 0
Intra-subtype heterogeneity shapes treatment response in -rearranged ALL across all age groupsAlina Hartmann, Claudia D. Baldus, Lorenz Bastian et al.|Unknown|2026Cited by 0